Evidence map›Paper›PMID 38147466›Full record

ArticleProtein science : a publication of the Protein Society2024

Structural and functional validation of a highly specific Smurf2 inhibitor.

Tanner M Tessier, Arvid Chowdhury, Zane Stekel, Julia Fux, Maria Augusta Sartori, Joan Teyra, Nick Jarvik, Jacky Chung, Igor Kurinov, Frank Sicheri and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Structural and functional validation of a highly specific Smurf2 inhibitor.Protein science : a publication of the Protein Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Tanner M TessierDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.ORCID 0000-0002-5284-1691
Arvid ChowdhuryDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Zane StekelDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Julia FuxDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Maria Augusta SartoriDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Joan TeyraIcosagen Cell Factory OÜ, Tartumaa, Estonia.ORCID 0000-0003-2816-339X
Nick JarvikDepartment of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
Jacky ChungDepartment of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
Igor KurinovNE-CAT, Department of Chemistry and Chemical Biology, Cornell University, Argonne, Illinois, USA.
Frank SicheriLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Sachdev S SidhuDepartment of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
Alex U SingerDepartment of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
Wei ZhangDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
University of Guelph · CAUniversity of Waterloo · CAUniversity of Toronto · CAArgonne National Laboratory · USIcosagen (Estonia) · EEMount Sinai Hospital · CA

Funding

User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2M
Pixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0M
CIHR PJT-162249NIGMS NIH HHS P30 GM124165NIH HHS S10 OD021527
6 · The paper itself

Abstract

Smurf1 and Smurf2 are two closely related member of the HECT (homologous to E6AP carboxy terminus) E3 ubiquitin ligase family and play important roles in the regulation of various cellular processes. Both were initially identified to regulate transforming growth factor-β and bone morphogenetic protein signaling pathways through regulating Smad protein stability and are now implicated in various pathological processes. Generally, E3 ligases, of which over 800 exist in humans, are ideal targets for inhibition as they determine substrate specificity; however, there are few inhibitors with the ability to precisely target a particular E3 ligase of interest. In this work, we explored a panel of ubiquitin variants (UbVs) that were previously identified to bind Smurf1 or Smurf2. In vitro binding and ubiquitination assays identified a highly specific Smurf2 inhibitor, UbV S2.4, which was able to inhibit ligase activity with high potency in the low nanomolar range. Orthologous cellular assays further demonstrated high specificity of UbV S2.4 toward Smurf2 and no cross-reactivity toward Smurf1. Structural analysis of UbV S2.4 in complex with Smurf2 revealed its mechanism of inhibition was through targeting the E2 binding site. In summary, we investigated several protein-based inhibitors of Smurf1 and Smurf2 and identified a highly specific Smurf2 inhibitor that disrupts the E2-E3 protein interaction interface.

Indexed as

UbiquitinUbiquitin-Protein LigasesBinding SitesHumansTransforming Growth Factor betaUbiquitinationTransforming Growth Factor betaUbiquitinUbiquitin-Protein Ligasescrystal structureE3 ligasesHECT domaininhibitorphage displayprotein engineeringubiquitin variants

Identifiers

PMID38147466
PMCPMC10823456
OpenAlexW4390225833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.